Subscribe or Manage Preferences


San Francisco, CA—Reductions in postinitiation treatment costs partly offset, but did not eliminate, the added cost of repository corticotropin injection (RCI) therapy for patients with systemic lupus erythematosus (SLE), researchers behind the analysis of an administrative claims database have found.
London, United Kingdom—Women with systemic lupus erythematosus (SLE) appear to have a higher risk for cervical cancer and premalignant cervical changes compared with women in the general population, according to the results of a large Swedish registry study presented at the 2016 annual meeting of the European League Against Rheumatism (EULAR). The highest risk was observed in women treated with immunosuppressive agents compared with those treated with antimalarial medications, the researchers also observed.
London, United Kingdom—Evidence is mounting in support of using the investigational monoclonal antibody anifrolumab in patients with severe systemic lupus erythematosus (SLE). Results from the phase 2b MUSE trial—which were first presented at the 2015 American College of Rheumatology Annual Scientific Meeting, and then in greater detail at the recent 2016 European League Against Rheumatism Annual Congress—show that in patients with moderate-to-severe SLE, anifrolumab reduces disease activity across a wide range of clinical end points, and is safe and tolerable.
Investigators behind a longitudinal study at a single center identified several risk factors for organ damage in patients with systemic lupus erythematosus (SLE), and demonstrated that organ damage compromises health-related quality of life (HR-QOL) in these patients. Factors such as preexisting damage at baseline, age, immunosuppressive drug use, cigarette smoking, and higher mean erythrocyte sedimentation and C-reactive protein (CRP) levels were associated with earlier organ damage; some of these risk factors are modifiable.
Lupus is an autoimmune disease that affects multiple parts of the body, and results in the immune system attacking healthy tissues. Symptoms of lupus, including painful joints, red rash, and extreme fatigue, differ from person to person, and appear in the form of a flare. Although symptoms can worsen despite taking medication, certain steps for preventing lupus flares can be beneficial. The following tips include methods for preventing the onset of a flare.
A recent systematic review suggests that taking action in a variety of nonpharmacologic ways can reduce fatigue associated with systemic lupus erythematosus (SLE).
It appears that unnecessary and avoidable serial routine laboratory tests are ordered for about 11% of patients with systemic lupus erythematosus (SLE) at each office visit, according to a recent survey of medical practices that treat these patients.
Despite the high direct medical costs of treating systemic lupus erythematosus (SLE), opportunities exist for improving SLE treatment rates, treatment appropriateness, and referral to specialists, according to research presented at the Academy of Managed Care Pharmacy annual meeting.
Belimumab is the first new drug for systemic lupus erythematosus (SLE) in more than 50 years and the first in its class to be approved by the US Food and Drug Administration (FDA).
Paris, France—A study presented at the 2014 European League Against Rheumatism (EULAR) Congress reports that a sizable proportion of selected patients with lupus can stop therapy without triggering new disease flares for up to 5 years.
Page 1 of 5
Results 1 - 10 of 41
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology